Tower Research Capital LLC (TRC) - VALEANT PHARMACEUTICALS INTL ownership

VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 588 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2015. The put-call ratio across all filers is 2.30 and the average weighting 1.4%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of VALEANT PHARMACEUTICALS INTL
ValueSharesWeighting
Q2 2018$82,000
+164.5%
3,540
+86.8%
0.01%
+66.7%
Q1 2018$31,000
-60.3%
1,895
-36.2%
0.00%
-70.0%
Q4 2017$78,000
-53.6%
2,972
-68.3%
0.01%
-28.6%
Q3 2017$168,000
+630.4%
9,363
+836.3%
0.01%
+366.7%
Q2 2017$23,000
+2200.0%
1,000
+900.0%
0.00%
Q1 2017$1,000
-93.8%
100
-91.2%
0.00%
-100.0%
Q4 2016$16,000
-96.9%
1,134
-94.7%
0.00%
-96.2%
Q3 2016$520,000
+303.1%
21,198
+231.0%
0.05%
+333.3%
Q2 2016$129,000
-18.4%
6,405
+6.7%
0.01%
-50.0%
Q1 2016$158,000
-50.0%
6,003
+93.0%
0.02%
-52.9%
Q4 2015$316,000
-61.4%
3,110
-9.6%
0.05%
-36.2%
Q3 2015$819,000
+116.7%
3,441
+102.4%
0.08%
+135.3%
Q2 2015$378,000
-82.8%
1,700
-80.7%
0.03%
-87.5%
Q1 2015$2,199,000
+2370.8%
8,789
+1301.8%
0.27%
+2922.2%
Q4 2014$89,000
-61.1%
627
-59.8%
0.01%
-65.4%
Q3 2014$229,000
+114.0%
1,560
+84.0%
0.03%
+85.7%
Q2 2014$107,000
-94.9%
848
-94.7%
0.01%
-94.8%
Q1 2014$2,117,000
+105750.0%
16,055
+114578.6%
0.27%
Q4 2013$2,000
-93.5%
14
-95.2%
0.00%
-100.0%
Q3 2013$31,000
-94.9%
294
-95.6%
0.00%
-94.0%
Q2 2013$610,0006,7240.05%
Other shareholders
VALEANT PHARMACEUTICALS INTL shareholders Q2 2015
NameSharesValueWeighting ↓
ACCIPITER CAPITAL MANAGEMENT, LLC 2,106,379$55,398,00031.67%
Claren Road Asset Management, LLC 80,000$2,820,00024.27%
Okumus Fund Management Ltd. 3,722,464$97,901,00015.82%
Wingspan Investment Management, LP 852,900$22,431,00012.66%
FARLEY CAPITAL L.P. 307,458$8,086,00011.46%
Chou Associates Management 976,843$25,725,0008.35%
Wingspan Investment Management, LP 550,700$14,483,0008.17%
HAP Trading, LLC 4,043,900$109,610,0008.00%
LeVasseur Capital Partners LLC 128,269$3,373,0006.97%
Pershing Square Capital Management 21,591,122$567,847,0006.41%
View complete list of VALEANT PHARMACEUTICALS INTL shareholders